390 papers
This study identifies salivary extracellular vesicle-derived miR-1307-5p as a biomarker of cisplatin resistance in oral squamous cell carcinoma and demonstrates that inhibiting this microRNA reverses drug resistance by targeting cancer stem cells and restoring sensitivity to cisplatin through the modulation of PI3K/AKT, MAPK/ERK, and YAP signaling pathways.
This study reveals that the REST-AKT-SOX2 axis drives tumor progression in Sonic-Hedgehog medulloblastoma by maintaining stem/progenitor cell identity and orchestrating extrinsic Midkine-mediated intercellular communication, thereby identifying this signaling pathway as a critical therapeutic target for suppressing tumor maintenance and chemoresistance.
This study demonstrates that the loss of RUNX1 drives immune-active ER+ breast tumorigenesis by activating interferon signaling and recruiting immune cells, a mechanism confirmed by both genetically engineered mouse models and human clinical data linking low RUNX1 expression to elevated immune signatures and poorer patient survival.
This study establishes the largest cohort of patient-derived mucinous ovarian carcinoma organoids to date, revealing their resistance to standard-of-care therapies and identifying alternative chemotherapeutic agents like gemcitabine, topotecan, and doxorubicin as promising candidates for personalized treatment.
This study demonstrates that a nanoparticle-delivered formulation of the TLR7/8 agonist resiquimod (ResiPOx) effectively penetrates the blood-brain barrier to reprogram tumor-associated myeloid cells, thereby activating anti-tumoral immunity and significantly improving survival in preclinical models of medulloblastoma and diffuse midline glioma.
This study identifies RAS-mutant clones as a key molecular driver of extramedullary acute myeloid leukemia (eAML), demonstrating that these mutations promote leukemic tissue infiltration and extramedullary growth through a JAML-PI3K/AKT signaling axis, thereby revealing AKT inhibition as a potential therapeutic strategy.
This study demonstrates that a specific low-intensity vibration regimen (90 Hz, 0.43 g, 15 min) suppresses breast cancer progression by reprogramming tumor transcriptomes to inhibit proinflammatory cytokines, disrupt motility signaling, and modulate miRNA expression, thereby converting malignant cells into a transient, non-invasive state.
This study identifies that SIRT5 overexpression in triple-negative breast cancer drives chemoresistance by orchestrating a metabolic switch that enhances nucleotide production and oxidative phosphorylation, while simultaneously creating a therapeutic vulnerability to ATR inhibition due to induced replication stress.
Long-term follow-up of the CASSIOPEIA trial reveals that while daratumumab improves outcomes for transplant-eligible multiple myeloma patients, transcriptomic risk stratification identifies a high-risk subgroup where MRD negativity fails to predict survival, highlighting the need for novel therapeutic strategies to address residual aggressive clones.
This study reveals that multiple myeloma and its treatments, including autologous stem cell transplant, durably reshape the bone marrow niche to impair immune reconstitution and vaccine responses, a defect that can be overcome by lipid nanoparticle-adjuvanted mRNA vaccines.
This study presents a scalable ex vivo platform using decellularized mouse organ scaffolds that preserves native tissue-specific matrix cues to accurately recapitulate organ-selective cancer cell invasion patterns, offering a cost-effective alternative to in vivo models for studying metastasis and testing therapies.
This study demonstrates that transcription factor-defined molecular subtypes govern both the initial response and acquired resistance to the DLL3-targeted T-cell engager tarlatamab in small cell lung cancer, revealing that ASCL1-positive tumors respond best while resistance often involves therapeutic selection for NEUROD1-high states with downregulated DLL3 expression.
This study demonstrates that serial radiofrequency ablation induces systemic antitumor immunity in pancreatic cancer by activating CD8+ T cells, but this response is constrained by a CSF1R-dependent myeloid resistance program that can be overcome through rational combination immunotherapy targeting PD-L1, CD73, and CSF1R.
This study demonstrates that CF10, a novel polymeric fluoropyrimidine, significantly outperforms standard 5-fluorouracil in overcoming resistance and toxicity by effectively targeting stem-like and invasive subpopulations in patient-derived colorectal cancer models, thereby offering a superior therapeutic index and survival advantage.
This study demonstrates that a single-section multiplexed imaging approach using a clinically informed antibody panel enables comprehensive, accurate, and tissue-efficient lung cancer diagnosis by simultaneously integrating tumor classification, biomarker assessment, and immune profiling while overcoming the limitations of traditional sequential testing.
This study demonstrates that adipocyte-derived signals reprogram triple-negative breast cancer cells by coupling metabolic rewiring with selective chromatin opening to activate stress-adaptive gene programs, thereby enhancing their ability to buffer oxidative stress and survive.
The orally available small molecule Alphataxin, an alpha-1 antitrypsin surrogate, significantly suppresses murine colon cancer and induces long-term remission when combined with anti-PD-1 therapy by increasing tumor-infiltrating CD4+ T cells and enhancing the release of IFN-γ, with no observed toxicity in rat studies.
This study elucidates how specific MANCR lncRNA isoforms regulate triple-negative breast cancer progression by interacting with p53 to modulate transcriptional activity, binding to distinct genomic regions, and potentially sponging miRNAs to influence androgen receptor expression.
This study demonstrates that intratumoral delivery of lipid nanoparticle-formulated mRNA encoding a membrane-bound IFNγ-FasICD fusion protein effectively drives tumor regression by simultaneously inducing direct Fas-mediated apoptosis in cancer cells and remodeling the tumor microenvironment to enhance systemic anti-tumor immunity.
This paper introduces a hierarchical graph neural network that leverages spatial transcriptomics to accurately distinguish between immunogenic and tolerogenic tertiary lymphoid structures in renal cell carcinoma, revealing that bulk CXCL13 expression often reflects non-TLS exhaustion rather than productive immunity and demonstrating the model's robustness through high clinical validation and cross-cancer generalization.